Altimmune (ALT) AI Stock Analysis

• Market Cap: $349.50M
• Dividend Yield: N/A
• Average Volume (3M): 2.83M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.77
• Revenue Growth: -95.11%
• EPS Growth: 27.25%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 88,257,256
• 10 Day Avg. Volume: 2,493,362
• 30 Day Avg. Volume: 2,827,718
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.42
• Enterprise Value/Revenue: 7.40K
• Enterprise Value/Gross Profit: -14.80K
• Enterprise Value/Ebitda: -1.66
• 1Y Price Target: $19.75
• Price Target Upside: 400.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 52 Neutral
• Price Target: $4.00 ▲(1.27% Upside)

Altimmune's overall stock score is primarily influenced by its financial challenges and valuation concerns, which are offset to some extent by positive developments in clinical trials and a strong cash position as highlighted in the earnings call. The technical analysis suggests a neutral market stance, providing neither strong bullish nor bearish signals.

Positive Factors

Clinical Trial Success

The success in the IMPACT trial for NASH resolution indicates strong potential for Altimmune's pipeline, enhancing its competitive position in the biopharmaceutical industry.

Strong Cash Position

A robust cash position provides Altimmune with the financial flexibility to invest in R&D and navigate clinical trials, supporting long-term growth and stability.

Advancement in Phase II Trials

Progress in Phase II trials for AUD and ALD suggests potential for new market opportunities, addressing unmet medical needs and expanding Altimmune's therapeutic portfolio.

Negative Factors

Negative Revenue Growth

Persistent negative revenue growth and margins highlight operational inefficiencies, posing a challenge to Altimmune's ability to achieve profitability and sustainable growth.

Regulatory Uncertainty

Uncertainty in regulatory pathways for noninvasive testing could delay product approvals, impacting Altimmune's ability to bring new therapies to market efficiently.

Cash Flow Challenges

Negative cash flows indicate ongoing financial strain, limiting Altimmune's ability to fund operations and invest in growth without external financing.

Altimmune Business Overview & Revenue Model

Company Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

Altimmune generates revenue primarily through the development of its therapeutic candidates, which may include milestone payments from partnerships with larger pharmaceutical companies. The company has engaged in collaborations and licensing agreements that provide upfront payments, research funding, and royalties on sales of products developed through these partnerships. Additionally, Altimmune may receive funding through government grants or contracts aimed at supporting the development of its vaccines and therapies, particularly those related to infectious diseases. As the company progresses its drug candidates through clinical trials and toward commercialization, potential revenue from product sales could become a significant source of income.

Altimmune Financial Statement Overview

Summary

Altimmune's financial performance reflects significant challenges typical of early-stage biotech firms. The income statement shows net losses and declining revenues, while the cash flow statement indicates substantial cash burn. Despite a strong equity position and low leverage, the firm relies heavily on external financing.

Income Statement

Altimmune's income statement reveals consistent net losses, with a worsening net profit margin over the TTM. Revenue has sharply declined from previous years, indicating significant challenges in revenue generation. The gross profit margin is negative, reflecting higher costs than revenues, a common issue in early-stage biotech firms focusing on R&D. The EBIT and EBITDA margins are deeply negative, highlighting limited operational efficiency and profitability.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio, indicating prudent financial management and low leverage risk. The equity ratio is high, supported by substantial stockholders' equity relative to total assets, suggesting financial stability. However, the recurring net losses impact the return on equity, which remains negative, reflecting challenges in generating shareholder value.

Cash Flow

Altimmune's cash flow statement underscores significant cash burn from operations, characteristic of R&D-intensive biotech companies. The operating cash flow and free cash flow are both negative, indicating the firm relies on external financing, which is partially mitigated by positive trends in financing cash flow. The company shows no significant free cash flow growth, posing a risk to long-term sustainability without continued external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.00K	20.00K	426.00K	-68.00K	4.41M	8.19M
Gross Profit	-10.00K	20.00K	-51.00K	-568.00K	-69.43M	-25.32M
EBITDA	-89.10M	-94.81M	-87.94M	-84.40M	-96.53M	-54.15M
Net Income	-87.75M	-95.06M	-88.45M	-84.71M	-97.09M	-49.04M
Balance Sheet
Total Assets	190.35M	139.31M	210.64M	206.93M	218.86M	245.12M
Cash, Cash Equivalents and Short-Term Investments	183.10M	131.89M	197.81M	184.88M	190.30M	215.92M
Total Debt	15.85M	1.68M	671.00K	1.12M	1.53M	1.82M
Total Liabilities	28.98M	15.80M	16.54M	21.64M	19.73M	19.24M
Stockholders Equity	161.37M	123.51M	194.10M	185.29M	199.13M	225.88M
Cash Flow
Free Cash Flow	-81.58M	-79.85M	-75.86M	-62.71M	-90.55M	-34.65M
Operating Cash Flow	-81.57M	-79.85M	-75.81M	-62.59M	-78.24M	-34.44M
Investing Cash Flow	110.84M	-28.39M	13.73M	-73.40M	87.52M	-72.09M
Financing Cash Flow	96.71M	10.04M	86.11M	56.78M	65.10M	213.49M

Altimmune Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.95
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALT, the sentiment is Neutral. The current price of 3.95 is above the 20-day moving average (MA) of 3.93, above the 50-day MA of 3.79, and below the 200-day MA of 5.02, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 52.14 is Neutral, neither overbought nor oversold. The STOCH value of 41.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALT.

Altimmune Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALT	52 Neutral	$349.50M	―	-55.91%	―	-95.11%	27.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENGN	42 Neutral	$414.65M	―	-43.95%	―	―	―
DMAC	42 Neutral	$346.83M	―	-73.41%	―	―	-31.78%
DRTS	38 Underperform	$342.19M	―	-43.83%	―	―	-21.92%
LXEO	38 Underperform	$498.43M	―	-75.32%	―	―	-20.53%
TVRD	37 Underperform	$49.04M	-0.30	-93.85%	―	-40.16%	78.28%

Altimmune Corporate Events

Altimmune Appoints New Chief Medical Officer

Altimmune, Inc. announced a leadership transition as Dr. Scott Harris, the former Chief Medical Officer, will retire on February 28, 2026. Christophe Arbet-Engels has been appointed as the new Chief Medical Officer, effective October 1, 2025. Dr. Harris will remain with the company as a Senior Strategic Advisor until his retirement, assisting in the transition of duties and continuing to receive his salary, benefits, and other compensations during this period.

The most recent analyst rating on (ALT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.

Altimmune Holds Annual Stockholders Meeting on Governance

On September 25, 2025, Altimmune, Inc. held its 2025 Annual Meeting of Stockholders, where 58.6% of the company’s shares were represented. The meeting included elections for directors, ratification of Ernst & Young LLP as the independent accounting firm, an advisory vote on executive compensation, and a vote to authorize adjournment to solicit additional proxies. The results showed varying levels of support for directors and proposals, reflecting shareholder engagement and decision-making in corporate governance.

The most recent analyst rating on (ALT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.

Altimmune’s Earnings Call Highlights NASH Trial Success and Financial Strength

Altimmune’s recent earnings call conveyed a largely positive sentiment, highlighting significant progress in clinical trials, particularly for NASH, and a robust financial position. Despite these advancements, the company faces challenges in achieving statistical significance for fibrosis improvement and navigating the regulatory landscape for noninvasive testing.

Altimmune Reports Promising Trial Results and Financial Growth

Altimmune, Inc. is a late clinical-stage biopharmaceutical company that focuses on developing peptide-based therapeutics for liver and cardiometabolic diseases, with its lead program being pemvidutide, a GLP-1/glucagon dual receptor agonist.